Stocktoria
CRESCENT BIOPHARMA, INC. CBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-01-10
CRESCENT BIOPHARMA, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $10.8M | — | $10,000 | $75,000 | $1.2M |
| R&D expense | $138.1M | $14.3M | $20.1M | $28.4M | $47.5M |
| Operating income | -$152.6M | -$40.0M | -$39.3M | -$47.4M | -$63.4M |
| Income tax | $2.0M | — | — | — | — |
| Net income | -$153.9M | -$37.9M | -$36.9M | -$46.7M | -$63.4M |
| EPS (diluted) | — | $-0.59 | $-0.58 | $-0.89 | $-1.23 |
| Operating cash flow | -$71.5M | -$31.1M | -$34.9M | -$46.5M | -$57.5M |
| Free cash flow | -$72.5M | -$31.1M | -$34.9M | -$46.5M | -$57.5M |
| Cash & equivalents | $213.2M | $34.8M | $41.8M | $47.9M | $90.3M |
| Total assets | $240.3M | $35.6M | $45.3M | $51.8M | $94.3M |
| Total liabilities | $37.3M | $47.1M | $6.9M | $8.9M | $12.7M |
| Shareholders' equity | $203.0M | -$15.5M | $38.4M | $42.9M | $81.6M |
Source: SEC EDGAR filings · CIK 0001253689 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.